Why the Medical Developments share price charged higher in October

Find out why the Medical Developments International Ltd (ASX: MVP) share price charged 17.7% higher as one of the October ASX winners.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medical Developments International Ltd (ASX: MVP) share price was one of the big gainers on the ASX last month.

The Aussie medical devices group had a huge month amid announcing a new CSIRO deal and several strong Penthrox updates.

Why did the Medical Developments share price charge higher?

The Medical Developments share price charged 17.7% higher to $5.85 per share by month-end. The big gains came in mid-October as the company updated the market on its Penthrox product.

Penthrox is an analgesic used by GPs, military forces and similar for emergency pain relief. It's commonly known as the "green whistle" due to the appearance of its hand-held inhaler.

The biggest boost for the Medical Developments share price came on 22 October after a key product update. The company's shares charged higher after Medical Developments reported strong Penthrox results from its European studies.

Just a day later on October 23, the Aussie company launched its signature product in Italy – the latest in a string of milestones.

This also triggered a US$2 million (A$2.9 million) payment from development partner Mundipharma which is expected in 2020.

In late October the company also signed a new Manufacturing Development Project with the CSIRO after 18 years of partnership. Medical Developments will invest up to $5 million over 5 years to develop new manufacturing technologies for pharmaceutical products.

Is November the time to buy?

The Medical Developments share price has outperformed the ASX 200 so far in 2019 after surging 39.44% higher.

The big red flag for me is just how expensive the company's shares are for what you're getting back in earnings.

The Medical Developments price-to-earnings (P/E) ratio is an astonishing 371x earnings, although these metrics can be flawed for growth companies.

Medical Developments has seen solid growth for the last 5 years as its shares have surged 371.43% to $5.94 per share.

However, I think I'd prefer to invest in a blue-chip name like CSL Ltd (ASX: CSL) given where we're at in the cycle right now.

Kenneth Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Medical Developments International Limited. The Motley Fool Australia has recommended Medical Developments International Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Farmer with arms folded looking ahead.
Broker Notes

What is Morgans' view on GrainCorp shares after monster sell-off?

Is it time to buy-low after the sell-off?

Read more »

Person handing out $50 notes, symbolising ex-dividend date.
Dividend Investing

Where I'd invest $10,000 into ASX dividend shares right now

I think these businesses are a strong buy for passive income.

Read more »

three men stand on a winner's podium with medals around their necks with their hands raised in triumph.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy end to the trading week this Friday.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A business person directs a pointed finger upwards on a rising arrow on a bar graph.
Share Gainers

3 ASX 200 stocks storming higher in this week's sinking market

Investors have sent these three ASX 200 stocks soaring this week. But why?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Market News

Why Aeris Resources, Netwealth, Nova Minerals, and Paragon Care shares are dropping today

These shares are under pressure on Friday. Let's find out why.

Read more »

Two smiling work colleagues discuss an investment at their office.
Share Gainers

Why 4DMedical, Develop Global, EOS, and Maas shares are racing higher today

These shares are ending the week on a high. But why?

Read more »

A man leans forward over his phone in his hands with a satisfied smirk on his face although he has just learned something pleasing or received some satisfying news.
Share Market News

Downer EDI wins $870m NZ highway maintenance contracts: What investors need to know

Downer EDI wins major New Zealand state highway maintenance contracts worth NZ$870 million, expanding its infrastructure portfolio.

Read more »